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Abstract 
Background: Mesenchymal stromal cells (MSC) may serve as an attractive therapy in renal transplantation due to 
their immunosuppressive and reparative properties. While most studies have used autologous MSCs, allogeneic MSCs 
offer the advantage of immediate availability for clinical use. This is of major importance for indications where instant 
treatment is needed, for example allograft rejection or calcineurin inhibitor toxicity. Clinical studies using allogeneic 
MSCs are limited in number. Although these studies showed no adverse reactions, allogeneic MSCs could possibly 
elicit an anti-donor immune response, which may increase the incidence of rejection and impact the allograft survival 
in the long term. These safety issues should be addressed before further studies are planned with allogeneic MSCs in 
the solid organ transplant setting.
Methods/design: 10 renal allograft recipients, 18–75 years old, will be included in this clinical phase Ib, open label, 
single center study. Patients will receive two doses of 1.5 × 106 per/kg body weight allogeneic bone marrow derived 
MSCs intravenously, at 25 and 26 weeks after transplantation, when immune suppression levels are reduced. The 
primary end point of this study is safety by assessing biopsy proven acute rejection (BPAR)/graft loss after MSC treat-
ment. Secondary end points, all measured before and after MSC infusions, include: comparison of fibrosis in renal 
biopsy by quantitative Sirius Red scoring; de novo HLA antibody development and extensive immune monitoring; 
renal function measured by cGFR and iohexol clearance; CMV and BK infection and other opportunistic infections.
Discussion: This study will provide information on the safety of allogeneic MSC infusion and its effect on the inci-
dence of BPAR/graft loss.
Trial registration: NCT02387151
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Background
Overall kidney graft survival has improved over the past 
decades, mainly as a result of improvement of first-year 
graft survival due to better immunosuppressive regi-
mens and overall medical care. However, long-term graft 
survival remained unaltered over the past two decades 
mainly because of graft loss due to interstitial fibrosis and 
tubular atrophy (IF/TA) [1]. The mechanism of IF/TA is 
thought to be a result of immunologic and non-immu-
nologic causes including calcineurin inhibitor toxicity. 
More recently, there has been a focus on antibody-medi-
ated rejection indicating an important role for humoral 
immunity in late kidney allograft failure [2–8].
In order to improve long term graft survival and mini-
mize side effects of the current immune suppressive 
agents, new therapies are sought. Mesenchymal stromal 
cell (MSC) therapy constitutes an attractive intervention 
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due to their immunosuppressive and reparative proper-
ties and their likely limited side effects [9]. In vitro stud-
ies imply that MSCs may play a role in modulation of 
immune responses. These beneficial immune modula-
tory effects have been confirmed in experimental mod-
els of allo- and autoimmune disorders, including allograft 
rejection [10–14]. First results of autologous bone mar-
row (BM) derived MSC therapy after human renal 
transplantation demonstrate safety and feasibility and 
illustrate their immune suppressive properties [15–22].
Most studies have used autologous MSCs. However, 
due to the expansion period, quality controls and logis-
tics, product manufacturing takes several weeks, which is 
a long period of time for patients in need for acute treat-
ment, for example in calcineurin toxicity and allograft 
rejection. Allogeneic MSCs offer the advantage of imme-
diate availability “off-the-shelf” for clinical use. Another 
benefit of using allogeneic MSCs is that the cells can be 
selectively derived from young donors. This is important 
because MSC number and functionality has been shown 
to decrease with age [23–25]. Importantly, a potential 
disadvantage of allogeneic MSC treatment could be the 
development of an anti-donor immune response, as has 
been described in experimental studies [26, 27]. There-
fore, it is necessary that we establish whether allogeneic 
MSC therapy in renal recipients is safe and does not 
evoke an anti-donor response, which might negatively 
impact graft function and survival. In the current pro-
tocol, allogeneic MSCs are infused at a time point where 
immune suppression levels are reduced and the graft is 
at increased risk for developing immune mediated injury. 
Additionally, a significant proportion of the grafts already 
has developed signs of fibrosis at this time, a process that 
might be reduced by the MSCs. Primary endpoints of this 
study include allograft rejection and graft loss. To mini-
mize the chance of development of anti-donor immune 
responses and thus allograft rejection our strategy is to 
select allogeneic MSCs, which have no similarity with the 
HLA mismatches between the kidney graft and the recip-
ient. A second criteria is that the recipient should have 
no preformed HLA antibodies directed to the MSCs in 
order to prevent immune destruction of the MSCs.
Methods and design
Objectives and endpoints
The primary endpoint of the current study is safety by 
assessing biopsy proven acute rejection (BPAR) and graft 
loss after allogeneic BM derived MSC treatment. The 
following secondary endpoints will be measured before 
and after MSC treatment: the level of fibrosis, as deter-
mined by quantitative Sirius Red (SR) scoring of renal 
biopsies; glomerular filtration rate (GFR) calculated by 
CKD-EPI formula and measured by iohexol clearance; 
Cytomegalovirus (CMV), BK infection (viremia, disease, 
syndrome and subtypes of BK viremia) and other oppor-
tunistic infections; the presence of anti-human leucocyte 
antigen (HLA) donor specific antibodies (DSA) and other 
phenotypical and functional aspects of the donor specific 
immune response.
Study design
The current trial is a 12-month, non-randomized, open-
label, prospective, single-center study. In total, 10 de novo 
renal recipients, 18–75  years of age, will be recruited 
from the transplant clinic of the Leiden University Medi-
cal Center (LUMC) and enrolled into the study if they 
meet the eligibility criteria. Ethical approval was obtained 
from the Dutch Central Committee on Research Involv-
ing Human Subjects (CCMO) and the Dutch competent 
authority.
Inclusion criteria
1. Female or male, aged between 18 and 75 years.
2. Subject is willing to participate in the study, must be 
able to give informed consent and the consent must 
be obtained prior to any study procedure.
3. Recipients of a first kidney graft from a living-unre-
lated or non-HLA identical living related donor.
4. Panel Reactive Antibodies (PRA) ≤50 %.
5. Patients must be able to adhere to the study visit 
schedule and protocol requirements.
6. If female and of child-bearing age, subject must be 
non-pregnant, non-breastfeeding, and use adequate 
contraception.
Exclusion criteria
 1. Double organ transplant recipients.
 2. BPAR in the 4 weeks before MSC infusion.
 3. Patients with evidence of active infection or 
abscesses (with the exception of an uncomplicated 
urinary tract infection) before MSC infusion.
 4. Patients suffering from hepatic failure.
 5. Patients suffering from an active autoimmune dis-
ease.
 6. A psychiatric, addictive or any disorder that compro-
mises ability to give truly informed consent for par-
ticipation in this study.
 7. Use of any investigational drug after transplantation.
 8. Documented HIV infection, active hepatitis B, hepa-
titis C or tuberculosis according to current trans-
plantation inclusion criteria.
 9. Subjects with an active opportunistic infection at the 
time of MSC infusion [e.g., herpes zoster (shingles), 
CMV, BK, Pneumocystis jirovecii (PJP), aspergillosis, 
histoplasmosis or mycobacteria other than tubercu-
losis].
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 10. Malignancy (including lymphoproliferative disease) 
within the past 2–5  years (except for squamous or 
basal cell carcinoma of the skin that has been treated 
with no evidence of recurrence) according to current 
transplantation inclusion criteria.
 11. Known recent substance abuse (drug or alcohol).
 12. Patients who are recipients of ABO incompatible 
transplants.
 13. Patients with severe total hypercholesterolemia 
(>7.5  mmol/L) or total hypertriglyceridemia 
(>5.6 mmol/L) (patients on lipid lowering treatment 
with controlled hyperlipidemia are acceptable).
All patients will receive alemtuzumab induction 
therapy at day 0 and day 1 (15 mg subcutaneously) and 
maintenance triple therapy consisting of prednisone, tac-
rolimus (Advagraf ), and everolimus (Certican). The tar-
get of the everolimus is 3–8 ng/mL. The tacrolimus target 
is 8–10  ng/mL the first 6  weeks after transplantation, 
4–7 ng/mL from week 6 to week 24 and will be reduced 
to targets of 1.5–3  ng/mL after week 24. Patients will 
receive two doses of a target of 1.5 × 106 selected alloge-
neic MSCs per/kg body weight at weeks 25 and 26 after 
transplantation.
Isolation of bone marrow and MSC production
MSCs for the study will be obtained from an independent 
third party donor according to the LUMC standardized 
and approved protocol. All donors will undergo routine 
examination and screening tests, according to the stand-
ard procedures required for BM donors in the LUMC. 
BM will be aspirated from the posterior iliac crest. A total 
volume of 100 to 120 mL will be harvested. The process-
ing and expansion of the cells will take place at the Good 
Manufacturing Practice (GMP) Facility of the LUMC. 
During the expansion process, population doubling time 
and cell numbers are monitored as a marker for popula-
tion fitness and functionality. After approval of in process 
and final product quality control results, the MSC prod-
ucts will be released for the clinical trial under a EU GMP 
manufacturers license. Final product release is based on 
the following criteria: surface marker expression (>90 % 
of cells CD73+/CD90+/CD105+, ≤1  % of cells CD45+ 
and ≤0.01  % of cells CD3+), absence of microbial con-
tamination using culture and mycoplasma PCR, spindle 
shaped morphology, a colorless cell suspension devoid of 
cell aggregates, no genetic abnormalities using karyotype 
analysis and viability.
Data collection
Patients enrolled in this study will undergo standard pre-
transplant work-up, which consists of baseline clinical 
data (demographics, medical history, current medication, 
previous blood transfusions, percentage of PRA, infec-
tion status, physical examination, laboratory examina-
tions, urinalysis, electrocardiogram and chest X-ray). 
For women, the menopausal status will be recorded and 
a pregnancy test will be done prior to transplantation if 
applicable.
Intraoperative data (warm and cold ischemia time, 
anatomy of donor and recipient) and background infor-
mation of the kidney donor (age, gender, race, height, 
weight, type of allograft (living related or unrelated), 
infection status, serum creatinine) and HLA (mis)
match will also be documented. All immunosuppressive 
and other drugs used and dosages administered will be 
recorded during the study.
Assessment schedule
Subjects will be seen in accordance with the assessment 
schedule listed in Table 1.
Infusion of MSCs
A clinical re-evaluation will be performed before the 
planned MSC infusion to rule out any contra-indication 
for administration. A target number of 1,5x106 MSCs 
per/kg body weight (range 1–2 × 106) will be infused IV 
within 30 min. Close monitoring of vital signs (tempera-
ture, pulse, respiratory rate, blood pressure and oxygen 
saturation) will be measured before, during and up to 2 h 
after MSC infusion.
(Opportunistic) infections
Hepatitis B, C and HIV status will be evaluated routinely 
within 6 months before transplantation.
CMV (PCR-positive), EBV (PCR-positive), BK-viruria 
in urine samples and BK-viremia in blood samples (RT-
PCR) will be measured as shown in Table 1. In addition 
subtypes of BK will be determined. Other infections 
(including urinary tract infections, pulmonary infec-
tions, herpes simplex) will be recorded as well. Patients 
are treated routinely with valganciclovir prophylaxis for 
6  months except in case of a CMV negative donor and 
recipient status. In addition, all patients receive 6 months 
of cotrimoxazole prophylaxis against PJP.
Renal function
GFR calculation will be used to determine the renal 
function [28]. The following abbreviated CKD-EPI for-
mula will be used for GFR estimation: eGFR [mL/
min/1.73m2] = 141 × min (SCr/k,1)α × max(SCr/k,1)−1.209  
×  0.993age ×  (1.018 if female) ×  (1.159 if black) (k is 0.7 
for females and 0.9 for males, α is −0.329 for females and 
−0.411 for males). In addition we will measure renal func-
tion with iohexol clearance at week 24 and week 52 after 
transplantation [29].
Page 4 of 8Reinders et al. J Transl Med  (2015) 13:344 
Renal biopsy
A standard renal protocol biopsy is performed at trans-
plantation (T = 0) and at 24 weeks after transplantation. 
At 52 weeks after transplantation a study biopsy is taken 
to assess the renal histology after MSC infusion. Biopsies 
are scored according to the Banff criteria and processed 
for immunohistochemistry (Hematoxylin and eosin 
staining; staining for CD3, CD4, CD68, FOXp3, C4d and 
CD20). Tissue will be embedded in paraffin and stained 
for Sirius Red [30]. The amount of cortical collagen (SR-
positive area) will be measured and finally expressed as 
the percentage of the total analyzed cortical surface.
Immune monitoring
DSA will be measured by luminex antibody screen-
ing and CDC/Flow crossmatch at baseline, before and 
after MSC infusion, and every time a for-cause allograft 
biopsy is performed. For immunological monitoring, 
sera and PBMCs will be collected at various time points 
post transplantation as described in Table 1. Phenotypi-
cal analyses of the different leucocyte subpopulations will 
be performed similar to our recently described protocol 
[22] on basis of the immune panels developed and vali-
dated for the One Study [31]. These panels identify differ-
ent subsets of T cells, B cells and DCs. In addition, PBMC 
proliferation assays will be performed sequentially with 
the use of frozen PBMCs obtained before transplantation 
to compare responses to the donor cells of the kidney 
donor before and after transplantation [32]. PBMCs will 
be stimulated using CD3/CD28 and analyzed for TH1 
(i.e. interleukin-2 and interferon-γ), TH2 (IL-10 and IL-4) 
and inflammatory cytokines (i.e. tumor necrosis factor-α, 
TGF-β, IL-1 and IL-6) [33]. The levels of a broad range 
of systemic pro-inflammatory and anti-inflammatory 
cytokines and chemokines will be measured by multiplex 
assays [34].
Risk–benefit assessment
With the use of allogeneic MSCs, renal recipients who 
have an acute indication for treatment could benefit 
from this therapy. A potential danger of allogeneic MSCs 
could be sensitization of the recipient and an increased 
risk for allograft rejection. We argue that the absence of 
significant alloimmune reactions in patients receiving 
allogeneic MSCs in previous trials [35, 36] and the time 
of MSC administration beyond 24  weeks after trans-
plantation in combination with accurate immune testing 
before MSC infusion warrant this study. In addition, spe-
cific HLA-mismatch criteria further minimize the risk of 
sensitization: MSCs will be selected to have no similarity 
with the HLA mismatches between the kidney graft and 
the recipient.
Discussion
In renal transplantation MSC therapy could be attrac-
tive in view of its potent effects on immune cells and its 
reparative properties. The addition of MSCs to the cur-
rent immune suppressive strategies could help reduce 
the level of the toxic immune suppressants and limit the 
fibrosis reaction and immune mediated injury. We envis-
age that this could be a step forward to prolong allograft 
survival. In this phase I study we will test whether the 
Table 1 Assessment schedule
BL baseline, Tx renal transplantation
a before and 4 h after MSC infusion
Week BL Tx W24 W25 W26 W27 W28 W30 W34 W38 W42 W46 W52
Informed consent X
Medical history X X
Transplantation information X
Concomitant medication X X X X X X X X X X X X X
Physical examination X X X X X X X X X X X X X
Routine lab X X X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X
CMV, EBV and BK viral load X X X X X X X
MSC infusion X X
Renal biopsy X X X
Iohexol clearance X X
Immune monitoring X X Xa Xa X X X
DSA X X X X X
Safety assesment X X X X X X X X X X X X X
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administration of selected allogeneic MSCs is safe and 
does not increase the incidence of BPAR and/or graft 
loss.
Allogeneic MSCs offer several key advantages over 
autologous MSCs, including the possibility of donor 
selection and availability “off-the-shelf” for clinical use 
without the delay required for expansion. However, a 
potential danger of allogeneic MSCs could be sensitiza-
tion with an increased risk for antibody mediated allo-
graft rejection [26, 27]. Therefore endpoints in our study 
are focused both on allograft rejection and on immune 
monitoring before and after MSC therapy. Immune mon-
itoring will be performed according to the methods vali-
dated in The One study as described by Streitz et al., and 
as also used in our recent Triton protocol where autolo-
gous MSCs are administered early after transplantation 
[22, 31]. For this immune monitoring strategy, six pan-
els are used to analyze the immune response, including 
the general immune status, T cell subsets, αβ +  T cells 
and γδ +  T cells, T cell activation, T cell memory and 
regulatory T cells. In addition, B cell and dendritic cell 
(DC) subsets will be measured. Besides this robust and 
validated immune monitoring, DSAs and their comple-
ment binding capacities will be determined at several 
time points. Various studies have reported the clinical 
relevance of the occurrence of anti-HLA antibodies and 
DSAs in transplantation setting [2–4, 7, 8]. A study per-
formed in 2009 reported a significantly lower 10-year 
graft survival in patients with DSAs after renal trans-
plantation compared to the DSA negative group (49 vs. 
83 %) [5]. More recent studies confirmed the importance 
of these de novo HLA specific DSA as a major cause of 
long-term allograft failure. In the majority of the stud-
ies, the incidence of de novo DSA is below 15 % [37, 38]. 
Not all DSAs, however, appear to be equally harmful. 
Antibodies directed at HLA class II and the capacity to 
fix complement appear to give worse outcome with more 
ABMR and higher risks of graft loss [39–42].
The formation of DSAs and the development of rejec-
tion after allogeneic MSC infusion has been reported in 
several animal studies especially with the use of donor 
derived MSCs [43–45]. In mice receiving an allogeneic 
BM transplantation the addition of autologous MSCs has 
been compared to donor derived MSCs. The infusion of 
donor MSCs was associated with a higher incidence of 
rejection of the BM transplant [43]. In another study, in 
renal transplantations in mice, increased allograft rejec-
tion was reported and an increase of DSAs was seen 
when donor derived MSCs were administered 4  days 
before transplantation [45]. In contrast, the use of third 
party MSCs caused long term heart graft survival in rats, 
even when retransplanted in a second host without the 
use of immune suppression [46].
In the human setting allogeneic MSCs have been 
proven to be safe in a clinical study for the treatment of 
acute kidney injury and also clinical studies in haemat-
opoiectic stem cell transplantation have reported no 
related severe adverse effects [14, 47, 48]. Allogeneic 
MSCs have also been used in the Poseidon trial where 
autologous and third party allogeneic MSCs for the 
treatment of ischemic cardiomyopathy were compared. 
Transendocardial injection of both autologous and allo-
geneic MSCs was safe with low rates of related adverse 
events. Importantly, only 1 patient developed low levels 
of de novo DSAs after allogeneic MSC injection [35]. Few 
studies have focused on allogeneic MSCs in transplant 
recipients. The increase in allograft rejection or DSAs 
was not reported in a recent pilot study where six renal 
transplant recipients received donor derived MSCs com-
bined with low dose tacrolimus. The therapy was safe and 
prevented acute rejection after renal transplantation [36], 
however the induction of HLA antibodies was not tested 
in this study.
To minimize the risk of an anti-donor immune 
response in our study, we have chosen in our protocol to 
use selected allogeneic MSCs based on the before men-
tioned HLA criteria. In addition, patients will receive 
alemtuzumab induction, which according to several stud-
ies might reduce the incidence of BPAR. As maintenance 
therapy a combination with everolimus is used. In a heart 
transplant model MSC monotherapy inhibited acute 
graft rejection and the combination of MSCs with rapa-
mycin induced donor-specific allograft tolerance. In the 
tolerant recipients, MSCs migrated to the transplanted 
heart and various lymphoid organs. In addition a high 
frequency of Tol-DCs and CD4+CD25+Foxp3+ T cells 
was found in these animals [49].
Besides extensive immune monitoring, an important 
secondary endpoint of our study is renal function before 
and after MSC treatment. In the study by Perico, renal 
function declined when the MSCs were administered 
7 days after transplantation [16]. The hypothesis was that 
the subclinical inflammatory environment of the graft 
post transplantation favoured recruitment and activation 
of the MSCs, and thereby promoting a pro-inflammatory 
milieu with eventual acute renal dysfunction. Because the 
renal dysfunction could depend on the timing of infu-
sion, in their next study MSCs were administered the day 
before kidney transplantation and in these patients no 
deterioration of renal function was seen [50]. Renal dys-
function was also not observed in our former study on a 
patient cohort that was treated more than 6 weeks after 
transplantation [17].
In addition, fibrosis in the allograft will be measured 
before and after MSC treatment since this is a hallmark of 
patients who develop allograft dysfunction [51]. It would 
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be of interest to test whether allogeneic MSCs influ-
ence this process and could serve as therapy for IF/TA. 
Moreover, CMV, BK and opportunistic infections, will be 
monitored before and after MSC treatment. In our previ-
ous small study we found an increased incidence of viral 
infections [17], however this was not observed in the 
study by Tan et al. [19].
In this study we use bone marrow derived MSCs. An 
interesting development for future studies is the great 
therapeutic potential of allogeneic stromal cells har-
vested from Wharton’s Jelly (WJ) of the human umbili-
cal cord [52, 53]. In comparison to bone marrow derived 
MSCs, the isolation efficiency from WJ MSCs is greater 
while they have also a higher proliferative capacity [54, 
55]. These are important properties since large number of 
cells is needed for MSC treatment. An additional option 
is to set up a bank of MSC donors, homozygous for the 
most common HLA haplotypes, which can provide a well 
matched MSC graft for a significant number of recipients 
[56].
Taken together, allogeneic MSC may be an important 
treatment option for recipients of a renal transplant, 
especially for indications where autologous MSCs can-
not be realized logistically. We however believe, that we 
should accurately study the immune response and inci-
dence of allograft rejection, which could be elicited by 
allogeneic MSCs, before we move on to larger studies.
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